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Neurobiology of Disease
Dramatic Reduction of PrPC Level and Glycosylation in
Peripheral Nerves following PrP Knock-Out from Schwann
Cells Does Not Prevent Transmissible Spongiform
Encephalopathy Neuroinvasion
Barry M. Bradford,1Nadia L. Tuzi,2M. Laura Feltri,3 Caroline McCorquodale,1 Enrico Cancellotti,1 and Jean C. Manson1
1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin, Midlothian EH25 9PS, United Kingdom, 2University of
Edinburgh, Biology Teaching Organisation, Darwin Building, Edinburgh EH9 3JU, United Kingdom, and 3San Raffaele Scientific Institute, DiBiT, 20132
Milan, Italy
Expression of the prion protein (PrPC) is a requirement for host susceptibility to the transmissible spongiform encephalopathies (TSEs)
and thought to be necessary for the replication and transport of the infectious agent. The mechanism of TSE neuroinvasion is not fully
understood, although the routing of infection has been mapped through the peripheral nervous system (PNS) and Schwann cells have
been implicated as a potential conduit for transport of the TSE infectious agent. To address whether Schwann cells are a requirement for
spread of the TSE agent from the site of infection to the CNS, PrPC expression was selectively removed from Schwann cells in vivo. This
dramatically reduced total PrPCwithin peripheral nerves by 90%, resulting in the selective loss of glycosylated PrPC species. Despite this,
139A andME7mouse-passaged scrapie agent strains were efficiently replicated and transported to the CNS following oral and intraperi-
toneal exposure. Thus, the myelinating glial cells within the PNS do not appear to play a significant role in TSE neuroinvasion.
Introduction
Transmissible spongiform encephalopathies (TSEs) are neu-
rodegenerative diseases characterized by neuronal loss, gliosis,
amyloid deposition, and vacuolar pathological hallmarks. TSE
diseases target and affect the CNS and usually present with
characteristic deposition of a protease-resistant isoform of the
host-encoded protein PrPC. TSEs are naturally acquired pe-
ripherally (Taylor et al., 1996; Bartz et al., 2003) and are asso-
ciated with prolonged incubation periods, during which the
infectious agent travels to the CNS (Kimberlin and Walker,
1980; Glatzel et al., 2002). Precisely which cells are involved in
TSE neuroinvasion is currently unknown, though the infec-
tious agent has been traced through the peripheral nervous
system (PNS) (Schulz-Schaeffer et al., 2000; McBride et al.,
2001) and Schwann cells have been implicated in this process
(Follet et al., 2002).
In experimental models of mouse-passaged scrapie, a lag
phase occurs after infection, during which the agent replicates in
the periphery, accumulating upon the follicular dendritic cells in
secondary lymphoid organs such as the spleen (Brown et al.,
1999). The invasion of the CNS either from the spleen or directly
from the site of infection has been proposed to be dependent on
a continuous chain of PrPC-expressing cells (Bla¨ttler et al., 1997;
Glatzel and Aguzzi, 2000; Race et al., 2000). Time course studies
of several experimental TSE strains have shown that PrPSc is first
detectable in the CNS within the spinal cord and medulla oblon-
gata, concurrent with transport via vagal and splanchnic nerves,
andTSE infectious agent has beendetected by bioassay in the PNS
throughout the time course of infection (Cole andKimberlin, 1985;
Beekes et al., 1998; McBride et al., 2001). Further studies traced
PrPSc deposition at various time points along these nerves from
the periphery to the CNS (Groschup et al., 1999) and the PNS has
been shown tomeet the requirements for the neuroinvasive route
(Kimberlin et al., 1983). Transgenic knock-out (KO) of PrPC
revealed that expression is required for a host to be susceptible to
TSE disease (Bu¨eler et al., 1993;Manson et al., 1994). Subsequent
studies revealed that the TSE agent is not transported within a
PrPC-deficient CNS (Aguzzi et al., 1997) and expression within the
PNS appears critical for neuroinvasion (Glatzel and Aguzzi, 2000).
The presence of PrPC in Schwann cells has been demonstrated
(Lemaire-Vieille et al., 2000; Follet et al., 2002) and it has been
suggested that this may be dependent upon PrP expression in
nerve axons (Ford et al., 2002). Moreover, Schwann cells have
been implicated as a possible route of transport following in vitro
studies which showed cultured Schwann cells capable of amplifi-
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cation and serial propagation of PrPSc (Follet et al., 2002; Archer
et al., 2004). Here we examined whether the expression of PrP in
Schwann cells is a requirement for TSE neuroinvasion. To ad-
dress this, we have developed a transgenic mouse model that
specifically lacks PrP in Schwann cells. These transgenic mice
were challenged both peripherally and intracerebrally with two
well characterized mouse-passaged scrapie agent strains, ME7
and 139A. We demonstrate that Schwann cells express the ma-
jority of PrP in the peripheral nerve but this expression is not an
absolute requirement forTSEneuroinvasion.
Materials andMethods
Production of Schwann cell PrP knock-
out mice. To produce Schwann cell PrP
knock-out mice the Cre/LoxP recombina-
tion system was used. Cre recombinase
(Cre) is a 38 kDa protein isolated from the
bacteriophage P1. Cre mediates site-specific
recombination of DNA sequences between
LoxP (locus of X-over of P1) sites. LoxP
sites are 34 bp sequences consisting of two
13 bp inverted repeats with an 8 bp asym-
metric spacer region which bestows direc-
tionality to the sequence [for review, see
Sauer (1993)]. These elements can be
combined to excise a functional endoge-
nous gene in vivo (Gu et al., 1994). Ex-
pression of Cre was controlled by the
myelin Protein Zero (P0) promoter and
intragenic regulatory elements. P0 is an
adhesion molecule of the Ig superfamily
and constitutes 50% of the protein con-
tent of peripheral myelin (Greenfield et
al., 1973). The murine promoter for the
P0 gene (Mpz) has been successfully used
in transgenic mice to drive Schwann-cell-
specific expression of reporter genes (Fel-
tri et al., 1996, 1999b) andCre (Feltri et al.,
1999a, 2002; Saito et al., 2003). TheP0-Cre
transgene was combined via selective
breeding with gene-targeted transgenic
mice in which exon 3 of the Prnp gene has
been flanked by unidirectional LoxP se-
quences (floxed), and the resultant trans-
genic allele was named PrPfl (Tuzi et al.,
2004). Compound transgenic mice pos-
sessing both PrPfl and P0-Cre transgenes
therefore undergo Cre-mediated excision of the Prnp exon 3,
including the complete PrPC coding sequence, in Schwann cells
and as such are referred to as Schwann cell PrP knock-out mice.
The inclusion of the LoxP sequences into the Prnp gene has been
extensively investigated previously and shown to have no effect
on PrPC expression or TSE disease in the absence of Cre (Tuzi et
al., 2004).
Generation and genotyping of compound transgenic mouse-
model. PrP fl mice were interbred with P0-Cre mice for successive
generations to produce compound transgenic mice homozygous
for PrPfl at the Prnp gene locus and also possessing the P0-Cre
transgene. Mice devoid of PrPfl [i.e., homozygous Prnpwild type
(wt)], P0-Cre, or both transgenic elements were also produced
during the breeding process and were assigned to various control
groups based on their genotype (Table 1). All animal studies and
breeding were performed via standard methods and conducted
under the provisions of theUKAnimals Scientific Procedures Act
1986 and approved by the Neuropathogenesis Division Ethical
ReviewCommittee. For genotyping of transgenicmice, DNAwas
extracted from tail tip tissue for PCR analysis. Tail biopsy samples
(0.5 cm) were taken under anesthesia from all animals at 28 (7)
d of age. DNAwas extracted from tail biopsy samples via DNeasy
blood and tissue kit (Qiagen). Postmortem tail tissue from inoc-
ulated animals was also collected and digested overnight at 37°C
in lysis buffer [300 mM sodium acetate, 1% SDS, 10 mM Tris, pH
8, 1 mM EDTA, 200 g/ml proteinase K (PK)] and subsequent
extraction was performed with an equal volume of 1:1 phenol/
chloroform. DNA was precipitated with isopropanol, washed
with 70% ethanol, and resuspended in 100 l of TE buffer [con-
taining the following (in mM): 10 Tris, 1 EDTA, pH 7.4]. PCR
analysis was performed for both PrPfl (Tuzi et al., 2004) and
P0-Cre (Feltri et al., 1999a) transgenes as described previously. All
animal genotypeswere confirmed before and after TSE challenge.
Figure 1. a, PCR analysis of DNA extracted from sciatic nerve tissue revealing Cre-mediated recombination in Schwann cell PrP
knock-out mice only. Lanes: 1, 1 kb DNA ladder (Invitrogen); 2, wt sciatic nerve; 3, Cre control sciatic nerve; 4 and 5, Schwann cell
PrP knock-out sciatic nerve; 6,wt tail tip PCR control; 7, PrP fl/fl tail tip PCR control; 8, PrP fl/wt Cre-Deleter tail tip PCR control; 9, H2O
PCR control. Band sizes indicated in base pairs: 167 bp 5 region upstream of PrP exon 3 (wt allele); 210 bp 5 region upstream of
Prnp exon 3 including loxP site (PrP fl allele); 315 bp 5 and 3PrP after Cre-mediated excision of exon 3 (Cre-mediated recombined
PrP fl allele). b, Western blot analysis of PrP expression in brain (top) and sciatic nerve (bottom) tissue using anti-PrP antibody
7A12. Samples: 1, 129/Olabrain; 2, floxedPrP control; 3, Schwanncell PrPknock-out, revealing reductionof total PrPand loss of PrP
glycoforms in PNS tissue; 4, Cre control; and 5, nontransgenic control. Approximate protein molecular weight markers given in
kilodaltons. c, Western blot analysis of wild-type brain (1) and sciatic nerve (3) and Schwann cell PrP KO sciatic nerve (2) following
N-glycosidase F (F) treatment (), when not treated (nt), or without enzyme treatment (). d, Relative PrP expression and
glycoform profile in brain and sciatic nerve of wild-typemice and Schwann cell PrP knock-outmice, normalized towild-type brain
expression level; diglycosylated (light gray), monoglycosylated (hatched), and unglycosylated (dark gray) species are indicated.
Error bars represent total expression level SEM.
Table 1. Experimental animal groups, showing genotype and resulting effect upon
PrP expression pattern
Group
Genotype
Phenotype (PrP
expression pattern)Prnp P0-Cre
Schwann cell PrP KO PrP fl homozygous Positive Removed only from
Schwann cells
Floxed PrP control PrP fl homozygous Negative Normal
Cre control PrP wild type Positive Normal
Nontransgenic control PrP wild type Negative Normal
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Transmissible spongiform encephalopathy exposure. Inocula
were produced as 10% brain homogenates from pools of tissue
collected from either terminal ME7- or 139A-infected mice.
Groups of animals of confirmed genotype (as displayed in Table
1) were inoculated at 20 (10) weeks of age with 20l of homog-
enate either intracerebrally under anesthesia or intraperitoneally.
Oral TSE exposure of mice was achieved with 100 l of homog-
enate presoaked onto a single standard food pellet. Mice were
isolated into individual cages during oral exposure period and
free food was withdrawn until the inoculation pellet was fully
consumed.
Clinical scoring, observation, and neuropathology. Mice were
observed for signs of clinical illness as described previously
(Bruce et al., 1991). Clinical scoring of experiments was per-
formed blind and animals were regenotyped postchallenge for
confirmation and assignation to groups. Disease incubation
times were calculated as the interval between inoculation and
positive clinical assessment of terminal TSE disease. Tissue for
neuropathological assessment was fixed in 10% formal saline for
a minimum of 48 h, processed, and embedded in paraffin. Six-
micrometer sections were cut and stained with hematoxylin and
eosin and scored for spongiform vacuolar
degeneration on a scale of 0–5 for gray
matter or 0–3 for white matter in 12 stan-
dard areas as previously described (Fraser
and Dickinson, 1967).
Data analysis. Group mean scores
were plotted against area to give represen-
tative lesion profiles using Excel software
(Microsoft). Group mean incubation pe-
riods were calculated and compared for
both 139A andME7 experiments. Incuba-
tion period data were analyzed by one-
way ANOVA between genotype groups
for each inoculum and route separately.
Statistical analysis was performed using
Minitab software (Minitab). Clinically
and pathologically confirmed scrapie
cases were used to derive the incubation
times and plotted as Kaplan–Meier sur-
vival curves.
Western blot analysis. Ten-percent (w/v)
brain and sciatic nerve homogenates were
prepared in Nonidet P-40 (NP40) buffer
(0.5% NP40, 0.5% sodium deoxycholate,
150 mM NaCl, 50 mM Tris-HCl, pH 7.5,
and 1 mM PMSF). Chemicals were
sourced from VWR International, unless
stated otherwise. Tissues were homoge-
nized in Dounce glass/glass homogenizers
and centrifuged at 16,000  g for 15 min
at 4°C, and supernatant was isolated. To-
tal protein assessed via Coomassie total
protein assay (Perbio Science). N-linked
glycan chains were removedwith peptide-
N-glycosidase F (New England Biolabs)
for 1 h at 37°C. PK-resistant PrP was iso-
lated with 20 g/ml PK (Roche) for 1 h at
37°C. Twenty-microgram total protein
samples were denatured at 90°C for 15
min in SDS sample buffer (Invitrogen),
separated on 12% Novex Tris-glycine
polyacrylamide gels (Invitrogen), and
transferred onto polyvinylidene fluoride membrane (Millipore)
by semidry electroblotting in transfer buffer (20% methanol, 39
mM glycine, 48 mM Tris, and 0.0375% SDS) performed at 2 mA/
cm2. Membranes blocked for 1 h in Western blocking reagent
(Roche). PrP was detected with antibodies 7A12 (Li et al., 2000)
and 8H4 (Zanusso et al., 1998) at 50 ng/ml. Primary antibody
detected via horseradish peroxidase-conjugated rabbit anti-
mouse IgG (Stratech Scientific) at 200 ng/ml and BM chemilu-
minescent blotting substrate (Roche) exposed to Lumi-Film
(Roche).
PrP densitometry and quantification. Western blots were
scanned using a Kodak Image Station IS440 (Kodak) and ana-
lyzed with Kodak 1D software for PrP quantification. Statistical
analyses were performed using Excel (Microsoft). PrP expression
data were calculated as a percentage change via comparison
against standard control samples and are quoted as approximate
values due to calculation from densitometric analysis of semi-
quantitative Western blot analysis.
PrPSc immunocytochemistry. Tissues were fixed in formal sa-
line, paraffin embedded, and microtome sectioned at 6 m. Sec-
tions were autoclaved at 121°C for 15 min and immersed in 98%
Figure 2. Phenotype investigation of Schwann cell PrP knock-out in transverse sciatic nerve sections. a, b, Detection of Cre-
mediated-galactosidase expression via X-Gal histochemistry (blue) counterstained with nuclear fast red in Cre control ROSA26-
positivemice (b) but not ROSA26mice lacking Cre (a). Images taken at20magnification. c,d, Detection of PrP C expression (red)
via immunofluorescence in myelin structures of Cre control mice (c) but not Schwann cell PrP knock-out mice (d). Scale bars, 20
m. e, f, Normalmyelinmorphology observed in both floxed PrP controlmice (e) and Schwann cell PrP knock-out transgenicmice
(f ). Scale bars, 5m.
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formic acid for 5min for antigen retrieval.
Sections were then incubated for 20 min
with normal goat serum (Stratech Scien-
tific) diluted 1:20 in PBS and PrP was de-
tected with anti-PrP antibody 6H4
(Prionics) overnight diluted to a final
concentration of 1 g/ml in PBS/0.1%
BSA (Sigma). Antibody binding was de-
tected with biotinylated goat anti-mouse
IgG (Stratech Scientific) at 2 g/ml in PBS/
BSA and the Vectastain Elite ABC Kit
(Vector Laboratories), visualized with
diaminobenzidine. Non-neural tissues
were processed with alkaline phosphatase-
conjugated goat anti-mouse IgG (Stratech
Scientific) and visualized with Vector Red
(Vector Laboratories). Sections were
counterstained with hematoxylin. Pic-
tureswere takenusing anEclipse E800mi-
croscope (Nikon) and Image Pro plus
software (Media Cybernetics).
PrPC immunofluorochemistry. Samples
were immersion fixed in 4% paraformal-
dehyde/0.25% glutaraldehyde in PBS,
embedded in optimal cryotomy tempera-
ture (O.C.T.) compound, and cryosec-
tioned on a Leica CM1850 (Leica) at 30
m. Sections were blocked for 1 h with
PBS/0.5%BSA/mouse onmouse Ig block-
ing reagent (Vector Laboratories). Mouse
on mouse Ig blocking reagent was re-
moved by washing with PBS/1 protein
concentrate (Vector Laboratories) incu-
bated for 2 hwith anti-PrP antibodies 7A12
and 8H4 at 1 g/ml in PBS/0.5 protein
concentrate. Primary antibody binding was detected with biotin-
ylated goat anti-mouse IgG (Stratech Scientific) secondary anti-
body at 2.5 g/ml in PBS/0.5% BSA/0.5 protein concentrate.
Secondary antibody binding was detected with streptavidin, Al-
exa Fluor 594 conjugate (Invitrogen) at 2 g/ml. Sections were
analyzed and imaged via laser scanning 5 Pa confocal microscope
(Carl Zeiss).
X-Gal histochemistry. To confirm Cre expression pattern, P0-
Cre mice were crossed with ROSA26 reporter mice (Mao et al.,
1999). Tissues from P0-Cre and ROSA26 double-positive or
ROSA26-positive-onlymice were dissected into ice-cold PBS and
fixed in 2% paraformaldehyde/0.2% glutaraldehyde in 5 mM eth-
ylene glycol bis(2-aminoethyl ether)-N,N,NN-tetraacetic acid
(EGTA), 2 mM MgCl2, 0.02% NP40, and 0.01% sodium deoxy-
cholate. Postfixation, tissues were washed in 2 mM MgCl2, 0.02%
NP40, and0.01%sodiumdeoxycholate inPBS and incubated at 4°C
overnight in 15% and then 30% sucrose in PBS. Tissues were em-
bedded in O.C.T. compound and cryosectioned on a Leica
CM1850 (Leica) at 30 m. Slides were stained by incubation at
37°C in 1 mg/ml 5-bromo-4-chloro-3-indolyl- -D-galacto-
pyranoside (X-Gal) dissolved in DMSO (Sigma), 5 mM potas-
sium ferricyanide, 5 mM potassium ferrocyanide, 2 mMMgCl2,
0.02% P40, and 0.01% sodium deoxycholate in PBS from 2 to
48 h. The staining reaction was stopped in 20mM EDTA in PBS
for 5 min and slides were counterstained with nuclear fast red
(Vector Laboratories).
Myelin morphological analysis. Tissues were perfusion fixed in
2% paraformalydehyde/2% glutaraldehyde in 0.1 M sodium ca-
codylate, pH 7.4, and postfixed for 1 hwith 1%osmium tetroxide
Figure 3. a–f, Kaplan–Meier survival curves following transmission of mouse-adapted scrapie strains 139A (a, c, e) and ME7
(b,d, f ) via intracerebral (a,b), intraperitoneal (c,d), andoral (e, f ) routes. Legend:, Schwann cell PrP knock-out;f, floxedPrP
control;Œ, Cre control;F, nontransgenic control.
Table 2. Statistical analysis of TSE incubation period
Inoculum Route
Variance ratio
(within controls)
% Difference in incubation period
(floxed PrP vs controls)
Variance ratio (Schwann cell PrP
knock-out vs controls)
% Difference in incubation period
(Schwann cell PrP knock-out vs controls)
139A Intracerebral 0.66 ns 1.52 5.50* 4.09
139A Intraperitoneal 3.22* 14.89 9.31** 15.84
139A Oral 0.46 ns 5.94 0.78 ns 5.65
ME7 Intracerebral 3.24* 9.35 16.15*** 8.36
ME7 Intraperitoneal 2.51 ns 10.00 10.65** 13.32
ME7 Oral 7.23** 11.44 3.43 ns 4.65
Following ANOVA of incubation period data, the statistical significance of the variance ratios produced were calculated using F tests. The levels of statistical significance are indicated: ns Not significant ( p 0.05); *p 0.05; **p 0.01;
***p0.001. The variance ratios andpercentagedifferences inmean incubationperiods aredisplayedbetweenSchwann cell PrP knock-outmice and combined control groups. For comparison, thepercentagedifference inmean incubation
periodswithin the control groupswas calculated as thedifferencebetween the largest outlying control group (floxedPrP) and the remaining control groups. Thedifference in incubationperiods observedbetweenSchwann cell PrP knock-out
mice and controls, following peripheral routes of inoculation (intraperitoneal and oral), is comparable to that observed among groups of animals expressing PrP normally, with similar statistical significance.
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in 0.1 M sodium cacodylate buffer, pH 7.4. Samples were embed-
ded in Araldite 502 (all chemicals from ElectronMicroscopy Sci-
ences) for sectioning and use in electron microscopy. Figures
were prepared using Photoshop CS3.
Results
PrPC expression in Schwann cell PrP knock-out mice
Cre-mediated recombination of the PrP transgene with exon 3
flanked by LoxP sites (PrPfl) in PNS tissue from Schwann cell PrP
knock-out mice was detected via standard PCR methods, as de-
scribed previously (Tuzi et al., 2004), revealing excision of the
PrPC coding region had occurred as expected in DNA extracted
from peripheral nerve (Fig. 1a). Routine PCR screening of tail tip
tissue from the same subjects revealed no detectable recombina-
tion. Expression level of PrPC was examined via Western blot
analysis and densitometry. The brain of Schwann cell PrP knock-
out mice was shown to be identical to control groups of floxed
PrP, Cre, and nontransgenic littermate control mice, unlike the
sciatic nerve in which PrP was dramatically reduced (Fig. 1b).
Further investigation of the sciatic nerve revealed that in wild-
type mice, total PrPC approximates to 25% the amount found in
brain. PrPC in the sciatic nerve favors the unglycosylated form
with 16% diglycosylated, 20% monoglycosylated, and 64% ung-
lycosylated PrP species as opposed to brain with 66% diglycosy-
lated, 14% monoglycosylated, and 20% unglycosylated when
detected with anti-PrP antibody 7A12. Densitometric analysis of
PrP expression revealed 90% reduction in total PrPC in the
PNS of Schwann cell PrP knock-out mice when compared with
wild-type PrP-expressing mice (Fig. 1d). Reduction of PrPC ex-
pression occurs in all glycoforms, to the extent that monoglyco-
sylated and diglycosylated PrPC were rarely visualized following
Western analysis of Schwann cell PrP knock-out nerves. Un-
glycosylated PrPC species within these nerves were detectable
after prolonged film exposure times (Fig. 1b). This result was
confirmed by PNGase-F treatment and densitometry analysis
(Fig. 1c).
The use of ROSA26 reporter mice confirmed the localization
of Cre activity in P0-Cre mice solely to Schwann cells in periph-
eral nerve (Fig. 2b) as reported previously (Feltri et al., 2002).
Localization of PrPC within cross-sectioned PNS nerve axons
revealed that PrPC was normally present in compact myelin and
outer Schwann cell cytoplasmic regions (Fig. 2c). PrPC was ab-
sent from these structures in nerves from Schwann cell PrP
knock-out mice (Fig. 2d). Morphological analysis revealed nor-
mal myelination of peripheral nerve axons in Schwann cell PrP
knock-out mice (Fig. 2f), thus no overt phenotype was detected
due to Schwann cell PrP knock-out other than the effects on PrP
expression and glycoform levels.
Effect of Schwann cell PrP knock-out on TSE disease
incubation period
Following oral inoculation with both 139A and ME7 strains of
agent, incubation period data in the Schwann cell PrP knock-out
group revealed no statistically significant difference from control
groups (Tables S1 and S2). A statistically significant difference
was detected in group mean incubation period between the
Schwann cell PrP knock-out group and the control genotype
groups following intracerebral and intraperitoneal 139A and
ME7 infection with the Schwann cell PrP knock-out group hav-
ing the longest mean incubation period, with intracerebral incu-
bation times 4–8% longer and intraperitoneal incubation times
13–16% longer. Following intraperitoneal 139A infection and
intracerebralME7 inoculation a statistically significant variation,
around the 5% level, was observed between the control groups. In
these experiments the floxed PrP group has the shortest mean
incubation period among the control genotype groups, with in-
traperitoneal incubation times 10–15% shorter than other con-
trol groups despite expressing PrP normally (Table 2). A wide
range of incubation periods were observed within genotype
groups in these experiments. Distribution analysis of these data
revealed statistically outlying individuals, these occurred rarely in
only 5 mice of a total of 191, in a non-genotype-specific manner
and only after peripheral challenge (Fig. 3). Such outliers are not
unusual in peripheral TSE challenges usingmice ofmixed genetic
background and the age range within the experimental design.
Effect of Schwann cell PrP knock-out on PrPSc deposition
Total amounts of PrPSc deposition were quantified via Western
blot analysis with prior PK digestion of whole brain homoge-
nates. The amount of PrPSc in the brains from Schwann cell PrP
knock-out mice is equivalent to the amount in brains from con-
trol group mice, occurring within the same incubation period
(Fig. 4). The detection of PrPSc, as amarker of the disease process,
revealed that Schwann cell PrP knock-out mice are equally capa-
ble of supporting the disease process as mice expressing PrPC
normally. The pattern of PrPSc deposition in the CNS and pe-
ripheral lymphoid tissues were also examined via standard im-
munocytochemical methods. No differences in localization,
pattern or intensity of PrPSc deposition were observed between
Schwann cell PrP knock-out and control genotype mice. Follow-
ing intracerebral inoculation PrPSc deposition was observed
throughout the brain and spinal cord cervical, thoracic and lum-
bar sections as well as in the germinal centers of the spleen,
suggesting that either anterograde transport of agent or hematog-
enous spread were unaffected (Fig. 5). PrPSc deposition was also
observed in germinal centers of the spleen, gray matter of the
spinal cord and throughout the CNS via oral and intraperitoneal
inoculation route (Fig. 6). Staining within the CNS was differen-
tiated solely by agent, with 139A resulting in a uniform deposi-
Figure4. Western blot analysis of PrP Sc deposition load in terminal brain samples. Samples:
1, Uninfected129/Ola; 2, Schwann cell PrP knock-out; 3, floxedPrP control; 4, Cre control; and5,
nontransgenic control. Densitometry revealed no significant differences in the amount of PK-
resistant PrP detectable between genotypes; similar results were obtained following oral and
intraperitoneal challenges. Approximate protein molecular weight markers are given in
kilodaltons.
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tion throughout the neuropil and ME7 revealing a stellate
perineuronal pattern, for review of prion strains see (Bruce, 2003;
Morales et al., 2007). No host-specific effect was observed there-
fore discounting any difference due to genotype.
Pathological examination of PrPSc deposition patterns re-
vealed that terminal Schwann cell PrP knock-out mice were in-
distinguishable from control group mice and also 129/Ola or
C57BL “parental” inbred mouse strains following both ME7 and
139A challenges. PrPSc deposition was also investigated during
the course of both intraperitoneal and oral challenges. Time-
points were selected representing the earliest time that PrPSc dep-
osition is observed in the CNS of both 129/Ola andC57BLmouse
strains. Following oral challenge 2 mice from each genotype
group were killed at 126 d after 139A infection and 216 d after
ME7 infection. These time-points were selected based on previ-
ous observations of early deposition of PrPSc occurring within
the CNS following oral challenge by these agents. PrPSc deposi-
tion in the brains of 139A orally challenged mice was first
observed in the red nucleus as expected (Fig. 7a,c), with no dif-
ference observed between Schwann cell PrP knock-out mice and
controls. This data suggests that transport of the infectious agent
to the CNS from the site of infection was occurring at the same
rate in Schwann cell PrP knock-outmice as controlmice express-
ing PrPC normally. Little or no PrPSc deposition was observed in
ME7 challenged mice at 216 d postinfection, preventing further
analysis of these data. These data were taken as an indication that
progression of disease in the mixed genetic background mice
used in this study was occurring slower than expected compared
with known data on disease progression in the parental inbred
strains namely 129/Ola and C57BL, and that the deposition of
PrPSc in the CNS in this model is a very late stage event. PrPSc
deposition was observed in peripheral lymphoid tissue such as
ileal Peyer’s patches and lymph nodes associated with the celiac–
superior mesenteric ganglion complex at these time points with
both agent strains (Fig. 7i,k). This demonstrates that peripheral
concentration or amplification of infection is effective in lym-
phoid tissues of both wild-type and Schwann cell PrP knock-
out mice.
Effect of Schwann cell PrP knock-out on vacuolar pathology
Vacuolation in standard brain areas was assessed and lesion pro-
file analyses constructed to determine whether the removal of
PrP expression from Schwann cells would affect strain targeting
abilities. Although there is slight variation in the results obtained
between genotype groups, no overt differences were observed
specifically between Schwann cell PrP knock-out mice and con-
trol groupmice (Fig. 8). These data reveal that disease-dependent
vacuolar spongiform change progresses with equivalent severity
in the same brain areas of Schwann cell PrP knock-out mice as
control groupmice. This result reveals that, similar to PrPSc dep-
osition pattern, strain targeting processes were unaffected.
Figure 5. a–l, Immunocytochemical detection of PrP Sc deposition in tissues from terminally infected Schwann cell PrP KOmice (a, c, e, g, i, k) and normal PrP-expressing control mice (b, d, f,
h, j, l ) following intracerebral 139A or ME7 challenge. Tissue sections: brain (hippocampus), longitudinal spinal cord showing deposition in gray matter tracts, and spleen showing deposition in
germinal centers. Anti-PrP antibody was visualized with DAB (brown) in CNS tissues and Vector Red (red) in spleen; tissue sections were counterstained with hematoxylin (blue). PrP Sc deposition
pattern in Schwann cell PrP knock-out animals was indistinguishable from control genotype mice in all tissues investigated.
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Discussion
The majority of PrPC in peripheral nerves has been postulated to
be derived solely from neuronal expression (Bendheim et al.,
1992), transported via fast axonal transport (Borchelt et al.,
1994), and localized specifically to the synapse and possibly nodes
of Ranvier (Kretzschmar et al., 2000). Studies have suggested that
glial cells do not express PrPC, as it could not be detected follow-
ing axon degeneration with Schwann cells still present (Moya et
al., 2005). In contrast PrPC expression in glial cells (Moser et al.,
1995) and specifically myelin of the CNS has previously been
reported (Mironov et al., 2003). Data from this study clearly at-
tributes the majority of PrPC expression in peripheral nerves to
myelin sheaths and myelinating cells. The removal of the PrP
coding sequence from Schwann cells has a very profound effect
on the expression of PrP in the PNS. A reduction of 90% total
PrPC was observed in the sciatic nerve compared with the wild
type. PrPC was recently postulated to have a pivotal role in
the maintenance of myelin integrity (Baumann et al., 2007). The
removal of PrPC expression from myelin forming cells in the
study presented here, however, revealed no overt deficit inmyelin
integrity ormorphology. Transmission frequencies of the genetic
elements suggest no prenatal mortality. Aging of Schwann cell
PrP knock-out mice to700 d old revealed no overt phenotype.
The function of PrPwithin Schwann cells therefore remains to be
defined.
Analysis of PrP expression in peripheral nerves from Schwann
cell PrP knock-out mice also revealed a striking loss of glycosy-
lated PrP species. The PrPC glycoform profile in sciatic nerve is
very different from that of the CNS, with a predominance of
unglycosylated PrP species. Removal of PrP expression solely
Figure 6. a–p, Immunocytochemical detection of PrP Sc deposition in terminal tissue sections from Schwann cell PrP KOmice (a, c, e, g, i, k,m, o) and normal PrP-expressing control mice (b, d,
f, h, j, l, n, p) following oral (a–l ) or intraperitoneal (m–p) 139A or ME7 challenge. Tissue sections: brain (hippocampus), longitudinal spinal cord showing deposition in gray matter tracts, and
spleen showing deposition in germinal centers. Following peripheral infection, the PrP Sc deposition pattern in Schwann cell PrP knock-out animals was again indistinguishable from control
genotype mice in all tissues investigated.
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from Schwann cells reduced bothmonoglycosylated and diglyco-
sylated PrP species to below definable and measurable levels in
the nerve as a whole. These data suggests that in the PNS the
processing of PrPC to complex glycoforms is predominantly per-
formed by Schwann cells and that nerve axons and other endo-
neurial cells appear to glycosylate little of the PrPC they may
express. This finding was consistently observed in all adult
Schwann cell PrP knock-out mice investigated with ages ranging
from 21 to 700 d old. The knock-out of PrP in this model likely
occurs during embryonic development and the regulation of ax-
onal protein expression and processing by Schwann cell glycop-
roteins has been shown previously (Dashiell et al., 2002);
therefore we cannot rule out the possibility that removal of PrP
expression from Schwann cells may affect PrP expression in as-
sociated nerve axons.
Removal of PrP expression from Schwann cells did not pre-
vent TSE neuroinvasion. Following oral infection with ME7 or
139A agent strains, no statistically significant differences in incu-
bation period were observed between Schwann cell PrP knock-
out mice and controls. A lengthening of incubation period was
observed in Schwann cell PrP knock-out mice following intra-
peritoneal challenge. The statistical significance of these results
however, is rendered obsolete due to the variation observed be-
tween control groups of mice via this route. Following direct
intracerebral challenge Schwann cell PrP knock-out groups re-
vealed a slight increase in group mean incubation period when
compared with control groups. These results suggest that oblig-
atory events occurring within the PNS may regulate disease
pathogenesis to a small degree. PrPSc deposition is observed in
the spleen at the terminal stage of disease; confirming that infec-
tion is not limited to the CNS following intracerebral inoculation
as described previously (Beekes and McBride, 2007). Via all in-
oculation routes, no differences in other disease criteria, such as
vacuolation or PrPSc deposition, were observed between Schwann
cell PrP knock-out mice and controls. The absence of any overt
effect on TSE disease neuroinvasion and pathogenesis following
removal of PrPC from Schwann cells and peripheral challenge
leads to a number of possible conclusions.
The first of these is that the PNS is not a conduit for the
transport of infectivity from the periphery to the CNS following
peripheral inoculation. However, much evidence exists to refute
this conclusion. The PNS has been implicated as an important
route of transport for the infectious agent to the CNS following
peripheral challenge (Kimberlin andWalker, 1980). PrPSc depo-
sition has been observed in the PNS from a variety of species
infected with TSE disease both naturally and experimentally par-
ticularly in experiments designed to trace the infectious routing
(Beekes et al., 1998;McBride et al., 2001) with early deposition of
PrPSc within the CNS finely targeted to specific areas. The local-
ization of PrPSc deposition within the PNS appears to be between
the nerve axon andmyelin sheath (Groschup et al., 1999) thereby
implicating both neuronal and glial cells in the transport of in-
Figure 7. a–l, Immunocytochemical detection of PrP Sc deposition in preclinical tissues following oral challenge (a, c, e, g, i, k); serial sections screened without anti-PrP antibody (ab) are
shown for comparison (b,d, f,h, j, l ). At 126d after 139Aoral challenge, PrP Sc depositionwas detected in the brain in the rednucleus (arrow ina), surroundingbut not insidemagnocellular neurons
(c). PrP Sc depositionwas detected onlywithin Peyer’s patches of ileal tissue (e,g). Investigation of the celiac–superiormesenteric ganglion (CSMG) complex revealed PrP Sc deposition in associated
lymph nodes (i, k).
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fection. Schwann-like cells in culture are capable of serial propa-
gation of the agent (Follet et al., 2002), suggesting that these cells
may be capable of agent propagation. The minimal effect follow-
ing intraperitoneal inoculation and absence of any increase in
incubation time following oral challenge however, question the
role of Schwann cells as an important routing to the CNS.
Another possibility is that PrPC expression is not a require-
ment for a cell to facilitate transport of infectivity. A number of
experimental approaches have implicated PrPC expression as a
requirement for neuroinvasion and transport of the infectious
TSE agent. Invasion of the CNS by the agent either from the
spleen, or directly from the site of infection is thought to be
dependent upon a continuous chain of PrPC-expressing cells
(Bla¨ttler et al., 1997; Glatzel and Aguzzi, 2000; Race et al., 2000).
The observation of neuritic transport of PrPSc in PrP-null cul-
tured neuronal cells (Magalha˜es et al., 2005), suggests that in vivo
there may be little requirement for PrPC expression in the PNS
for the transport of TSE infection. Moreover, axonal degenera-
tion and incomplete nerve regeneration does not affect TSE agent
transport along peripheral nerve conduits (Kratzel et al., 2007),
questioning whether nerve axons or PrPC are required for trans-
port of the infectious agent through the peripheral nervous sys-
tem. Again the alterations observed via the intraperitoneal route
would at best argue for the peripheral nerves being only a minor
component of the route to the CNS. We have established in par-
allel studies that while mice expressing
only unglycosylated PrP can become in-
fected with a TSE agent following intrace-
rebral challenge (Tuzi et al., 2008), they
are not capable of TSE neuroinvasion fol-
lowing peripheral routes of inoculation
(EC, BMB and JCM unpublished data)
thus implicating glycosylated PrP as im-
portant in the peripheral phases of infec-
tion (replication and/or transport). Itmay
be the case that fully glycosylated PrP is a
requirement for agent replication in the
periphery but is not a requirement for
agent transport, or vice versa.
The experiments described here have
raised further significant questions con-
cerning the role of the various cell types
within the PNS in uptake, transport, or
replication of the infectious TSE agent. It
may be the case that previous experiments
have shown only part of the overall pic-
ture of replication and transport of the in-
fectivity in the periphery and that other
routes such as blood may be significantly
more important than has been previously
recognized. We are addressing this possi-
bility in ongoing studies. If the PrPC ex-
pressed and glycosylated by Schwann cells
is not required for TSE neuroinvasion,
then nerve axons alonemay constitute the
neuroinvasive route. The highly repro-
ducible targeting of TSE agent strains to
specific areas of the CNS following pe-
ripheral infection suggests that little lat-
eral spread of infection occurs between
nerve axons during neuroinvasion. The
ability of a particular cell to become in-
fected, or contribute to the disease pro-
cess, may be unrelated to the relative amount or glycoform of
PrPC it expresses. The factors determining the susceptibility of a
particular cell type to TSE infection are therefore yet to be
determined.
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